

MAY 05 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sandor LOVAS et al.) Group Art Unit: 1653
Serial No.: 10/695,382) Examiner: Unassigned
Confirm. No.: 5299)
Filed: 28 October 2003)
For: NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND
PHARMACEUTICAL COMPOSITIONS THEREOF

FACSIMILE TRANSMISSION TO THE PTO

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FAX NUMBER: (571) 273-8300
Total Pages (including cover page): 16
Time: 12:25 pm (**Central Time**)

(Transmission must be complete by midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission:

- Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (3 pgs)
 - Exhibit A (3 pgs)
 - Exhibit B (2 pgs)
 - Paper Copy of Sequence Listing (5 pgs)
 - copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence (2 pgs)
 - Small Entity Status is entitled to be asserted in the above-identified application.**

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Muetting, Raasch & Gebhardt, P.A.

Customer Number: 26813

May 5, 2006

By *J. M.*

By: Ann M. Musting

Ann M. Mueller
Rec. No. 33-977

Reg. No. 55,977
Direct Dial (613)305-1217

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 5 day of May, 2006 at 12:25 PM (Central Time).

5 May 2006

Signature: Kelly J. McCarthy

Printed Name: Patricia McNulty

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

RECEIVED
CENTRAL FAX CENTER

MAY 05 2006

PATENT
Docket No. 180.0005 0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sandor LOVAS et al.) Group Art Unit: 1653
)
Serial No.: 10/695,382) Examiner: Unassigned
Confirm. No.: 5299)
)
Filed: 28 October 2003)

For: NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND
PHARMACEUTICAL COMPOSITIONS THEREOF

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants are in receipt of the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed 06 March 2006 from the OIPE division of the U.S. Patent and Trademark Office. Please note that this is the third such "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" Applicants have received in connection with this application.

The first "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" was mailed 04 February 2004 and Applicants responded on 02 April 2004 by filing a *Preliminary Amendment* with a *Request for Transfer of Computer Readable Form of Sequence Listing* (copies of which are enclosed as "Exhibit A" and "Exhibit B", respectively).

Response to Notice to Comply with Requirements...

Page 2 of 2

Applicant(s): Sandor LOVAS et al.
Serial No.: 10/695,382
Filed: 28 October 2003
For: NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF

In consideration thereof, Applicants were unclear why a second "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" was mailed on 10 August 2004. In response to this second notice, Applicants' Representatives contacted Ms. Anne-Marie Corrigan (ph: 571-272-2501) of the STIC System Branch for further clarification. Ms. Corrigan reviewed the case and found that, on 18 May 2004, the OIPE sent the STIC division a transfer statement that authorized the transfer of the sequence listing from the parent case (U.S. Serial No. 09/269,954; issued as U.S. Patent No. 6,664,369 B1 on 16 December 2003) to the instant application. This authorization was processed on 19 May 2004 and there were no errors reported in the Sequence Listing.

In consideration thereof, Ms. Corrigan confirmed that the second "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed 10 August 2004 was sent in error and no further response is necessary. In the interest of maintaining a complete file history, Applicants submitted a Response on 08 October 2004 indicating this information.

However, now a third "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" has been received, with a mailing date of 06 March 2006. Applicants' Representatives again contacted the Patent Office, first by contacting Ms. Robinson (ph: 517-272-4000) at the OIPE. Ms. Robinson did not believe this third "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" was necessary and attempted to contact the contractors holding this case for further clarification. After repeated telephone calls to Ms. Robinson, she was unable to verify the validity of this notice, so Ms. Anne-Marie Corrigan (ph: 571-272-2501) of the STIC System Branch was contacted again. Ms. Corrigan suggested submitting a paper copy of the sequence listing as a final attempt to satisfy the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures."

Response to Notice to Comply with Requirements...

Page 2 of 3

Applicant(s): Sandor LOVAS et al.

Serial No.: 10/695,382

Filed: 28 October 2003

For: NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF

In accordance thereof, enclosed herewith is a paper copy of the Sequence Listing as filed in the parent application, U.S. Serial Number 09/269,954 (U.S. Pat. No. 6,664,369).

This initial paper copy is identical to the computer readable disk in the parent application (the transfer of which was authorized and processed on 19 May 2004 to the present application) and includes no new matter.

A Preliminary Amendment specifically directing the entry of this sequence listing into the application was filed on 02 April 2004 ("Exhibit A").

We assume the issues presented in the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" are now satisfied. If, however, the Examiner finds any problems or errors with this submission, we request that the Examiner please contact the undersigned attorney directly to discuss this matter.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 5th day of May 2006, at 12:25 pm (Central Time).

Signature: Kathy J. McNeely
Printed Name: Kathy J. McNeely

Respectfully submitted
By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Telephone (612)305-1220
Facsimile (612)305-1228
Customer Number 26813

May 5, 2006
Date

AMM/kjm

By: Ann M. Mueting
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217

RECEIVED

Page 1 of 2

015

CENTRAL FAX CENTER

MAY 05 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/695,382	10/28/2003	Sandor Lovas	180.0005 0102

CONFIRMATION NO. 5299

26813
 MUETING, RAASCH & GEBHARDT, P.A.
 P.O. BOX 581415
 MINNEAPOLIS, MN 55458

FORMALITIES
 LETTER

Date Mailed: 03/06/2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>
 For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450
 Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

Pharmacy Sis

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 2 - COPY TO BE RETURNED WITH RESPONSE